Welcome

Clozapine & LAI Virtual Forum
February 7, 2024 | 4:00 – 4:45 pm ET

The Clozapine & LAI Virtual Forum is a peer-to-peer, interactive dialogue between psychiatrists, nurse practitioners, and other prescribing clinicians.

It is informal, no registration required — just join our Zoom call and share your challenges and questions on the month's trending topic around either clozapine or LAIs.

TODAY’S TOPIC:
Comparing Aripiprazole LAI Products
Moderators

**Donna Rolin, PhD, APRN, PMHCNS-BC, PMHNP-BC**
SMI Adviser Nursing Expert; University of Texas, Austin

Dr. Donna Rolin is Clinical Associate Professor and the Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Texas with 23 years of experience in psychiatric nursing, including inpatient, community, forensic, and older adult settings.

**Robert Cotes, MD**
SMI Adviser Physician Expert; Emory University

Dr. Robert Cotes, MD, is an Associate Professor at Emory University School of Medicine in the Department of Psychiatry and Behavioral Sciences. He has interest in clozapine, characterizing persistent symptoms of schizophrenia, understanding cardiometabolic side effects of antipsychotic medications, and first episode psychosis.

**Megan Ehret, PharmD, MS, BCPP**
SMI Adviser Pharmacist Expert; University of Maryland, Baltimore

Dr. Megan Ehret is a Professor at University of Maryland School of Pharmacy in the Department of Practice, Sciences, and Health Outcomes Research and is Co-Director of the Mental Health Program. She is a Past-President of the American Association of Psychiatric Pharmacists. Her current interests include psychotropic medication adherence and the incorporation of the psychiatric pharmacist in practice.
Discussion Questions for Virtual Forum: Comparing Aripiprazole LAI Products

• We now have 3 Aripiprazole LAIs

• With which of these LAIs are you familiar or have seen prescribed?
• Which are you (or colleagues) prescribing and why?
  • Aripiprazole Monohydrate (monthly)
  • Aripiprazole Monohydrate (bimonthly)
  • Aripiprazole Lauroxil (Q4, 6, or 8 weeks)

• How do you select between the various Aripiprazole products?
• What are your thoughts on having this many such LAI agents available?
<table>
<thead>
<tr>
<th></th>
<th>Aripiprazole Monohydrate (monthly)</th>
<th>Aripiprazole Monohydrate (bimonthly)</th>
<th>Aripiprazole Lauroxil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year approved</td>
<td>2013</td>
<td>2023</td>
<td>2015</td>
</tr>
<tr>
<td>Other indications</td>
<td>Bipolar disorder</td>
<td>Bipolar I maintenance</td>
<td>No</td>
</tr>
<tr>
<td>Injection sites</td>
<td>Deltoid or gluteal</td>
<td>Gluteal</td>
<td>Deltoid (441 mg dose) or gluteal</td>
</tr>
<tr>
<td>Needle gauge</td>
<td>21G, 22G, or 23G</td>
<td>21G or 22G</td>
<td>20G or 21G</td>
</tr>
<tr>
<td>Injection volume</td>
<td>2 mL (400 mg)</td>
<td>2.4 mL to 3.2 mL</td>
<td>1.6 to 3.9 mL</td>
</tr>
<tr>
<td>Injection frequency</td>
<td>Every 4 weeks</td>
<td>Every 8 weeks</td>
<td>Every 4 weeks (all doses), every 6 weeks (882 mg), or every 2 months (1064 mg)</td>
</tr>
<tr>
<td>Starting dose</td>
<td>400 mg</td>
<td>960 mg</td>
<td>441, 662, 882, or 1064 mg</td>
</tr>
<tr>
<td>Maintenance dose</td>
<td>300 or 400 mg (adjust for CYP2D6 or CYP3A4 issues)</td>
<td>720 or 960 mg</td>
<td>441, 662, 882, or 1064 mg (adjust for CYP2D6 or CYP3A4 issues)</td>
</tr>
<tr>
<td>Oral supplement</td>
<td>Yes-14 days</td>
<td>Yes- 14 days if patient is not switching from aripiprazole monohydrate monthly No-if patient is switching from aripiprazole monohydrate monthly Yes- 21 days if Aristada Initio is not utilized No- if Aristada Initio is utilized, one 30 mg dose is required upon initiation</td>
<td></td>
</tr>
<tr>
<td>Reconstitution</td>
<td>Yes; dual-chamber syringe now available</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Refrigeration</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Observation</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>
Aripiprazole- Aristada Initio®

- Prodrug of N-hydroxymethyl aripiprazole, which in turn is a prodrug of aripiprazole
- LinkeRx
- Nano-crystalline milled dispersion of aripiprazole lauroxil
- Increased rate of dissolution- enhancing bioavailability – faster time to therapeutic concentration
- Minimize the need for oral aripiprazole treatment overlap dosing:
  - 30 mg oral aripiprazole on day 1
  - Aristada Initio® 675 mg on day 1
  - Aristada® injection (441, 662, 882, 1062 mg) on same day as above or up to 10 days after

SMI ADVISER ASSETS ON LONG-ACTING INJECTABLES

Long-Acting Injectable Center of Excellence

Welcome to the Long-Acting Injectable (LAI) Center of Excellence (COE)

SMI Adviser created the LAI COE to promote the safe and effective use of LAIs. The ultimate goal of this effort is to improve the lives of individuals who have schizophrenia, schizoaffective, and bipolar disorders. The LAI COE provides clinicians with training opportunities, technical assistance, and vetted resources. These include:

- Live and on-demand webinars
- Virtual Learning Collaboratives
- Virtual Forums
- Email listserv
- On-demand consultations
- Intensive consultation to sites or communities
- Clinical tips and resources

The LAI COE is led by SMI Nursing Expert, Donna Rolin, PhD, APRN, SMI Adviser Physician Expert, Robert Cotes, MD, and SMI Adviser content partner, National Association of State Mental Health Program Directors (NASMHPD), and supported by members of the LAI Work group.

For individual and family resources on using long-acting injectables, visit the individual and family Knowledge Base.
LAI DOSE CONVERSION TOOL

LAI Med and Dose
- Initial 8 weeks: 210 mg Zyprexa Relprevv every 2 weeks or 405 mg every 4 weeks
- Maintenance: 150 mg Zyprexa Relprevv every 2 weeks or 300 mg every 4 weeks

Hint
Dose reduction may be necessary for CYP450 interactions of side effect intolerance.
FEEDBACK
Please help us improve the Clozapine & LAI Virtual Forum by completing this survey:
http://smiadviser.org/forumfeedback

Pre-submit Cases
www.smiadviser.org/vfcases

UPCOMING VIRTUAL FORUM
3/6/24 @ 4:00-5:00 PM ET
Clozapine Topic
For additional questions and resources – join the Clozapine and LAI Centers of Excellence Exchange Community

www.smiadviser.org/cloz_lai_signup
FEEDBACK
Please help us improve the Clozapine & LAI Virtual Forum by completing this survey: http://smiadviser.org/forumfeedback

Pre-submit Cases
www.smiadviser.org/vfcases

UPCOMING VIRTUAL FORUM

3/6/24 @4:00-5:00 PM ET
Clozapine Topic
For additional questions and resources – join the Clozapine and LAI Centers of Excellence Exchange Community
- www.smiadviser.org/cloz_lai_signup